<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00773786</url>
  </required_header>
  <id_info>
    <org_study_id>ASRC956</org_study_id>
    <nct_id>NCT00773786</nct_id>
  </id_info>
  <brief_title>Effect of Brovana and Tiotropium in Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
  <official_title>A Double-Blind, Crossover Study to Assess the Effects of Nebulized Brovana Added to Tiotropium on FEV1, Hyperinflation, and Exercise Endurance Capacity in COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Saint Francis Care</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sunovion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Saint Francis Care</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a double-blind crossover trial in 20 patient with stable COPD. Data from this
      study will provide proof-of-concept information on whether the (anticipated) additional
      bronchodilator effect of Brovana added to tiotropium will lead to a meaningful improvement in
      the patient-centered outcome, exercise capacity. This study will only evaluate the effects of
      short-term (1-week) administration of Brovana. If results are positive, it would provide
      preliminary data for further, multicenter investigations.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypotheses to be tested:

      Brovana nebulized twice daily added to maintenance inhaled tiotropium therapy in stable COPD
      patients increases:

        1. Forced expiratory volume in 1 second (FEV1) at peak dose effect (approximately 2 hours
           after AM dosing in the laboratory)

        2. Resting and exercise hyperinflation at peak dose effect (inspiratory capacity (IC) at
           baseline and at iso-time during exercise testing; these measurements will be
           approximately 2 ¼ hours after AM dosing of tiotropium plus test drug.

        3. Exercise treadmill endurance time at peak dose effect (approximately 2 ¼ hours after AM
           dosing in the laboratory)

      Patients: Twenty patients will be studied

      Location: Section of Pulmonary and Critical Care, St. Francis Hospital &amp; Medical Center,
      Hartford, CT

      Excluded drugs:

        1. Anticholinergic bronchodilators other than once-daily (AM) tiotropium at standard dose

        2. Long acting beta agonist bronchodilators

        3. Short acting beta agonist bronchodilators must be withheld within six hours of
           laboratory testing

      Allowed drugs:

        1. Inhaled steroids

        2. Oral steroids 10 mg/day or less, at stable dose for four weeks

      Removal of patients from study:

        1. Withdrawal of consent

        2. Documented oxygen desaturation &lt; 85% or clinically significant problems (such as angina,
           significant electrocardiogram (ECG) changes, etc) during any exercise testing

        3. A significant adverse event

        4. Protocol violation including lack of adherence

      COPD exacerbations during study:

      If the patient experiences a COPD exacerbation during the study which requires a change in
      medication or an addition of medication (such as oral steroids or antibiotics) the study will
      be held until stability is reached. At that time, the study will resume, beginning with new,
      1-week treatment /testing corresponding to the study sequence when the exacerbation began. If
      the patient does not resume stability within four weeks or has a second exacerbation, the
      study will be terminated.

      Study design: This will be a double-blind, crossover, single-site study in COPD patients who
      are in stable condition. All patients in study randomized to test drug by Visit 2 will have
      been on steady-state tiotropium therapy, off commercial long-acting beta-agonists (LABA), and
      using prn short-acting beta-agonists (SABA). Only acute (i.e., 1-week) effects of Brovana
      will be studied. SABA will be withheld from midnight before testing on each day.

      Exercise testing and inspiratory capacity (IC) measurements Incremental and steady-state
      endurance testing will be performed on a treadmill in the Section of Pulmonary and Critical
      Care Medicine. The incremental test (Visit 1) will be performed to a symptom-limited maximum,
      with a goal to have the test duration over approximately 10 minutes. The protocol used for
      this will be from Porszasz et al using simultaneous increases in treadmill speed and incline,
      with settings based on estimated maximal workrate. Warm-up will be 1 mph at 1% grade. This
      will be followed at 30-second intervals by increases in speed and incline. Patients will have
      breath by breath measurements of expired air using our Sensormedics equipment, via a
      mouthpiece. IC measurements will also be measured at rest and at every minute into exercise.

      Endurance tests (Visit 2, 4, 5) will be at 75% of the maximal rate determined from the
      initial test. For exercise capacity, duration in exercise time will be the primary outcome
      variable. IC will be measured at rest and at every minute during exercise.

      An ECG will be performed before each exercise test, and continuous pulse oximetry will be
      monitored. A physician will be in attendance at each test.

      Primary Efficacy Variables:

        1. Change in FEV1 near peak effect (~ 2 hours of AM laboratory dosing of tiotropium plus
           test drug):

             1. The primary comparison will be Δ FEV1 (@ 2-hours after Tiotropium + Brovana minus
                pre-dose FEV1) versus Δ FEV1 (@2-hours after Tiotropium + Placebo minus pre-dose
                FEV1)

             2. The analysis will be performed using a repeated-measures design, PROC GLM Repeated,
                SAS:

        2. Change in treadmill endurance time at ~75% of maximum (Δ endurance time) Brovana versus
           placebo: from baseline testing on tiotropium alone compared to testing on tiotropium +
           study drug.

             1. The primary comparison will be Δ endurance time (@ 2 ¼ hours after Tiotropium +
                Brovana compared to tiotropium alone

             2. The analysis will be performed using a repeated-measures design, PROC GLM Repeated,
                SAS

        3. Change in static (resting), iso-time, and peak exercise IC measurements, which will be
           used as our estimates of hyperinflation; Brovana versus placebo: from baseline testing
           on tiotropium alone compared to testing on tiotropium + study drug.

           a. The primary co-comparisons will be: i. Δ IC at rest (static hyperinflation) (@ 2 ¼
           hours after Tiotropium + Brovana compared to tiotropium alone ii. Δ IC at iso-time
           (static hyperinflation) (@ 2 ¼ hours after Tiotropium + Brovana compared to tiotropium
           alone. We are not sure what iso-time we will use, but if all patients go six minutes
           into exercise, we will use the six minute mark.

           b. The analyses will be performed using a repeated-measures design, PROC GLM Repeated,
           SAS

      Sample Size Estimation The van Noord sited earlier powered their study assuming a ~ 140 mL
      standard deviation for paired differences in FEV1 (determined from earlier trials), a
      difference of ~ 50 mL, and a power of 0.90. They achieved a 150 mL (0.150 L) difference in
      FEV1. For our study, using a difference of 150 mL, a standard deviation of 140 mL, and a
      power of 0.80, 16 patients would be sufficient.

      In a study by O'Donnell et al the combination of fluticasone 250 mcg / salmeterol 50 mcg was
      compared to salmeterol alone and placebo. Outcome variables included spirometry, lung volumes
      and exercise endurance time at 75% of maximal on a cycle ergometer. The average improvement
      (compared to placebo) in FEV1 at Day 1 (taken from graph) was about 200 mL with both the
      combination and salmeterol. The treatment-difference improvement in exercise endurance time
      with the combination was 131 ± 31 seconds (p. &lt; 0.004), representing a 22% improvement. For
      salmeterol alone it was 49 ± 37 seconds. Our study would use a treadmill rather than a cycle
      ergometer; this will probably lead to more dyspnea-limitation than leg fatigue limitation. We
      predict the Δ FEV1 at two hours post dosing (compared to tiotropium alone) with Brovana +
      tiotropium in our study will ~ 150 mL - a Δ not too dissimilar to the O'Donnell study Δ. To
      detect a 90 second difference in endurance time (1/2 way between 131 seconds and 49 seconds),
      and assuming a standard deviation (SD) of 35 seconds, our study would be amply powered.

      Study Sequence

      Visit 1:

        1. Informed consent obtained

        2. Inclusion/exclusion criteria met

        3. History and physical examination performed

        4. Post-bronchodilator spirometry for inclusion criteria

        5. Patient started on tiotropium, if necessary; tiotropium dispensed, if necessary

        6. If necessary: long acting bronchodilators (LABA) discontinued, ipratropium discontinued

        7. Levalbuterol MDI dispensed for prn use

        8. Appointment given for Visit 1

      Visit 2: 1 day (for patients already on tiotropium) to 1 week (those starting tiotropium)
      after Visit 1:

        1. Brief history and limited physical

        2. Spirometry on maintenance tiotropium, before AM dosing and after having SABA withheld
           for ~ 6 hours

        3. Incremental treadmill endurance test

        4. Patient instructed to continue taking tiotropium once daily in the morning (qAM) and
           levalbuterol MDI prn

        5. Appointment for 2-week follow-up

      Visit 3: 1 week after Visit 2, after maintenance tiotropium

        1. Brief history and limited physical

        2. Pre-bronchodilator spirometry (on maintenance tiotropium, levalbuterol withheld)

        3. Tiotropium given (open label)

        4. Spirometry 2 hours after tiotropium dosing

        5. ECG 2 ¼ hour after tiotropium dosing

        6. Endurance treadmill endurance test (including IC measurements) 2 ¼ hour after open-label
           tiotropium dosing

        7. Nebulizer dispensed

        8. Blinded Test drug # 1 dispensed (Brovana or placebo, 20 unit doses), instructions to
           take it via nebulizer bid, tiotropium continued qAM, levalbuterol MDI continued prn

        9. Appointment for 1 week follow-up

      Visit 4: 1 weeks after Visit 3, after test drug # 1

        1. Brief history and limited physical

        2. Pre-dosing spirometry (on maintenance tiotropium and Test Drug #1, levalbuterol
           withheld)

        3. Tiotropium and Test Drug # 1 given

        4. Spirometry 2 hours after above dosing

        5. ECG 2 ¼ hour after above dosing

        6. Endurance treadmill endurance test 2 ¼ hour after above dosing

        7. Begin wash-out period: Tiotropium open-label plus prn levalbuterol continued; placebo
           given via nebulizer, to be taken bid (this part is single-blinded)

        8. Appointment for 1 week follow-up

      Visit 5: 1 week after Visit 4, after washout

        1. Brief history and limited physical

        2. Spirometry in AM

        3. Blinded Test drug # 2 dispensed (Brovana or placebo, 20 unit doses), instructions to
           take it via nebulizer bid, tiotropium continued qAM, levalbuterol MDI continued prn

        4. Appointment for 1 week follow-up

      Visit 6: 1 week after Visit 5, after test drug # 2

        1. Brief history and limited physical

        2. Pre-dosing spirometry (on maintenance tiotropium and Test Drug #2, levalbuterol
           withheld)

        3. Tiotropium and Test Drug #2 given

        4. Spirometry 2 hours after above dosing

        5. ECG 2 ¼ hour after above dosing

        6. Endurance treadmill endurance test and IC measurements 2 ¼ hour after above dosing

        7. Study terminated
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2008</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</measure>
    <time_frame>baseline and 1 week</time_frame>
    <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Inspiratory Capacity at 1 Week</measure>
    <time_frame>baseline and 2 hours after dosing</time_frame>
    <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>Arformoterol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arformoterol twice daily for 1 week via nebulizer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo twice daily for 1 week</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arformoterol (Brovana)</intervention_name>
    <description>twice daily via nebulizer added to maintenance daily tiotropium</description>
    <arm_group_label>Arformoterol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo twice daily for 1 week (added to maintenance tiotropium)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Informed consent (Approval by the St. Francis Hospital Institutional Review Board
             (IRB) will be required before study initiation)

          2. Adults, age &gt; 40 years

          3. A clinical diagnosis of COPD, with spirometric confirmation: post-bronchodilator
             forced expiratory volume in 1 second / forced vital capacity (FEV1/FVC) ( &lt; 0.70

          4. Moderate, severe and very severe airflow limitation by GOLD criteria.

          5. Clinically stable respiratory disease

          6. The perceived ability to participate in pulmonary testing and exercise testing

          7. COPD, stable state

        Exclusion criteria:

          1. Women of childbearing potential

          2. Asthma

          3. Supplemental oxygen use or anticipated oxygen desaturation &lt; 85% at peak exercise
             (patients who desaturate below 85% on the incremental study will be excluded)

          4. Co-morbidity that would interfere with the patient participating in the study,
             including the exercise testing. Examples include unstable cardiac disease, arthritis,
             psychological problems that would interfere with participation

          5. An exacerbation requiring therapy or any change in maintenance COPD therapy within six
             weeks of testing

          6. A history of a prolonged QT interval

          7. Recent exacerbation of COPD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard ZuWallack, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Saint Frnacis Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>St Francis Hospital and Medical center</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2008</study_first_submitted>
  <study_first_submitted_qc>October 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 16, 2008</study_first_posted>
  <results_first_submitted>May 29, 2013</results_first_submitted>
  <results_first_submitted_qc>May 19, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 3, 2015</results_first_posted>
  <last_update_submitted>May 19, 2015</last_update_submitted>
  <last_update_submitted_qc>May 19, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <keyword>Bronchodilator</keyword>
  <keyword>arformoterol</keyword>
  <keyword>tiotropium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Tiotropium + Arformoterol (Brovana), Then Tiotropium + Placebo</title>
          <description>Participants first received Tiotropium + Brovana twice daily for 1 week via nebulizer. After a 1 week washout period, they received Tiotropium + placebo twice daily for 1 week.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Arformoterol (Brovana)</title>
          <description>Participants first received Tiotropium + Placebo twice daily for 1 week . After a 1 week washout period, they received Tiotropium + Brovana twice daily for 1 week via nebulizer.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Intervention (1 Week)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Study Participants</title>
          <description>Participants randomized and received either Tiotropium + Brovana twice daily for 1 week or Tiotropium + placebo twice daily for 1 week.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI)</title>
          <units>Kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26" spread="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Forced Expiratory Volume in 1 second (FEV1)</title>
          <units>percent-predicted</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53" spread="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</title>
        <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
        <time_frame>baseline and 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) at 1 Week</title>
          <description>Change from baseline in Forced Expiratory Volume in 1 second (FEV1) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline)</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" spread="0.048"/>
                    <measurement group_id="O2" value="0.010" spread="0.040"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.121" spread="0.037"/>
                    <measurement group_id="O2" value="0.023" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</title>
        <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
        <time_frame>baseline and 1 week</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Forced Vital Capacity (FVC) at 1 Week</title>
          <description>Change from baseline in Forced Vital Capacity (FVC) after 1 week on Brovana or Placebo. (Change = 1 week - baseline)</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0120" spread="0.072"/>
                    <measurement group_id="O2" value="0.000" spread="0.091"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="0.062"/>
                    <measurement group_id="O2" value="-0.062" spread="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Inspiratory Capacity at 1 Week</title>
        <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
        <time_frame>baseline and 2 hours after dosing</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Brovana (Arformoterol)</title>
            <description>Participants who received Tiotropium + Brovana twice daily for 1 week via nebulizer</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants who received Tiotropium + Placebo twice daily for 1 week</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Inspiratory Capacity at 1 Week</title>
          <description>Change from baseline in Inspiratory Capacity (IC) after 1 week on Brovana or Placebo (measured 2 hours post dose). (Change = 1 week - baseline).</description>
          <units>Liters</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Trough to trough</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.001" spread="0.898"/>
                    <measurement group_id="O2" value="-0.019" spread="0.647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Peak to peak</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.113" spread="0.063"/>
                    <measurement group_id="O2" value="-0.004" spread="0.042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>One week for each intervention</time_frame>
      <desc>Adverse event data was collection on all participants randomized into an intervention</desc>
      <group_list>
        <group group_id="E1">
          <title>Arformoterol</title>
          <description>Arformoterol twice daily for 1 week via nebulizer</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo twice daily for 1 week</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard ZuWallack, MD</name_or_title>
      <organization>Saint Francis Hospital and Medical Center</organization>
      <email>rzuwalla@stfranciscare.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

